Brief: DiaMedica Therapeutics Announces That The FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
21/06/2023 13:28
June 21 (Reuters) - DiaMedica Therapeutics Inc DMAC.O :
* DIAMEDICA THERAPEUTICS ANNOUNCES THAT THE FDA HAS REMOVED
THE
CLINICAL HOLD ON DM199 PHASE 2/3 TRIAL FOR ISCHEMIC STROKE
* DIAMEDICA THERAPEUTICS INC - PREPARATIONS ARE UNDERWAY TO
RESUME
REMEDY2 TRIAL AS SOON AS POSSIBLE
Source text for Eikon: ID:nBw4Xs96Ga
Further company coverage: DMAC.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program